Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (151-160 of 257) with videos related to

Pageof 26
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2022
Pharmacology of orismilast, a potent and selective PDE4 inhibitorJonathan I Silverberg, Lars E French, Richard B Warren, et al.
The British Journal of Dermatology|March 16, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Duc Binh Phan, Philip Laws, Catherine H Smith, et al.
The Journal of Investigative Dermatology|March 27, 2021
Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy ShowcaseZenas Z N Yiu, Jonathan N W N Barker, Michael R Barnes, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
Dermatology and Therapy|October 31, 2025
Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised EvidenceHeber Rew Bright Bright, Duc Binh Phan, Amna Zahid, et al.
The British Journal of Dermatology|February 8, 2023
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trialsGeorgios Kokolakis, Richard B Warren, Bruce Strober, et al.
JAMA Dermatology|December 6, 2023
Risk of Paradoxical Eczema in Patients Receiving Biologics for PsoriasisAli Al-Janabi, Oras A Alabas, Zenas Z N Yiu, et al.
Pageof 26

Showing results (151-160 of 257) with videos related to

Sort By:
Pageof 26
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2022
Pharmacology of orismilast, a potent and selective PDE4 inhibitorJonathan I Silverberg, Lars E French, Richard B Warren, et al.
The British Journal of Dermatology|March 16, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Duc Binh Phan, Philip Laws, Catherine H Smith, et al.
The Journal of Investigative Dermatology|March 27, 2021
Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy ShowcaseZenas Z N Yiu, Jonathan N W N Barker, Michael R Barnes, et al.
The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Adalimumab in Plaque PsoriasisRichard B Warren, Andrew Blauvelt, Jerry Bagel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Clinical and Experimental Dermatology|May 24, 2025
Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasisMark Lebwohl, Melinda J Gooderham, Richard B Warren, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
Dermatology and Therapy|October 31, 2025
Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised EvidenceHeber Rew Bright Bright, Duc Binh Phan, Amna Zahid, et al.
The British Journal of Dermatology|February 8, 2023
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trialsGeorgios Kokolakis, Richard B Warren, Bruce Strober, et al.
JAMA Dermatology|December 6, 2023
Risk of Paradoxical Eczema in Patients Receiving Biologics for PsoriasisAli Al-Janabi, Oras A Alabas, Zenas Z N Yiu, et al.
Pageof 26